PTEN and neoplasm: As previously documented, tumours affected by the combined loss of Pten and Trp53 are insensitive to the majority of therapies available in the clinic for PCa, such as androgen deprivation and docetaxel, and it is therefore surprising to observe that PF-03084014 is highly effective in this tumour background51.